PURPOSE: A major factor limiting the effective clinical management of colorectal cancer (CRC) is resistance to chemotherapy. Therefore, the identification of novel, therapeutically targetable mediators of resistance is vital. EXPERIMENTAL DESIGN: We used a CRC disease-focused microarray platform to transcriptionally profile chemotherapy-responsive and nonresponsive pretreatment metastatic CRC liver biopsies and in vitro samples, both sensitive and resistant to clinically relevant chemotherapeutic drugs (5-FU and oxaliplatin). Pathway and gene set enrichment analyses identified candidate genes within key pathways mediating drug resistance. Functional RNAi screening identified regulators of drug resistance. RESULTS: Mitogen-activated protein kinase signaling, focal adhesion, cell cycle, insulin signaling, and apoptosis were identified as key pathways involved in mediating drug resistance. The G-protein-coupled receptor galanin receptor 1 (GalR1) was identified as a novel regulator of drug resistance. Notably, silencing either GalR1 or its ligand galanin induced apoptosis in drug-sensitive and resistant cell lines and synergistically enhanced the effects of chemotherapy. Mechanistically, GalR1/galanin silencing resulted in downregulation of the endogenous caspase-8 inhibitor FLIP(L), resulting in induction of caspase-8-dependent apoptosis. Galanin mRNA was found to be overexpressed in colorectal tumors, and importantly, high galanin expression correlated with poor disease-free survival of patients with early-stage CRC. CONCLUSION: This study shows the power of systems biology approaches to identify key pathways and genes that are functionally involved in mediating chemotherapy resistance. Moreover, we have identified a novel role for the GalR1/galanin receptor-ligand axis in chemoresistance, providing evidence to support its further evaluation as a potential therapeutic target and biomarker in CRC.
PURPOSE: A major factor limiting the effective clinical management of colorectal cancer (CRC) is resistance to chemotherapy. Therefore, the identification of novel, therapeutically targetable mediators of resistance is vital. EXPERIMENTAL DESIGN: We used a CRC disease-focused microarray platform to transcriptionally profile chemotherapy-responsive and nonresponsive pretreatment metastatic CRC liver biopsies and in vitro samples, both sensitive and resistant to clinically relevant chemotherapeutic drugs (5-FU and oxaliplatin). Pathway and gene set enrichment analyses identified candidate genes within key pathways mediating drug resistance. Functional RNAi screening identified regulators of drug resistance. RESULTS: Mitogen-activated protein kinase signaling, focal adhesion, cell cycle, insulin signaling, and apoptosis were identified as key pathways involved in mediating drug resistance. The G-protein-coupled receptor galanin receptor 1 (GalR1) was identified as a novel regulator of drug resistance. Notably, silencing either GalR1 or its ligand galanin induced apoptosis in drug-sensitive and resistant cell lines and synergistically enhanced the effects of chemotherapy. Mechanistically, GalR1/galanin silencing resulted in downregulation of the endogenous caspase-8 inhibitor FLIP(L), resulting in induction of caspase-8-dependent apoptosis. Galanin mRNA was found to be overexpressed in colorectal tumors, and importantly, high galanin expression correlated with poor disease-free survival of patients with early-stage CRC. CONCLUSION: This study shows the power of systems biology approaches to identify key pathways and genes that are functionally involved in mediating chemotherapy resistance. Moreover, we have identified a novel role for the GalR1/galanin receptor-ligand axis in chemoresistance, providing evidence to support its further evaluation as a potential therapeutic target and biomarker in CRC.
Authors: Kiyoshi Misawa; Yo Ueda; Takeharu Kanazawa; Yuki Misawa; Ilwhan Jang; John Chadwick Brenner; Tetsuya Ogawa; Satoru Takebayashi; Reidar A Grenman; James G Herman; Hiroyuki Mineta; Thomas E Carey Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Rolf I Skotheim; Guro E Lind; Outi Monni; Jahn M Nesland; Vera M Abeler; Sophie D Fosså; Nur Duale; Gunnar Brunborg; Olli Kallioniemi; Peter W Andrews; Ragnhild A Lothe Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Donal P McLornan; Helen L Barrett; Robert Cummins; Ultan McDermott; Cliona McDowell; Susie J Conlon; Victoria M Coyle; Sandra Van Schaeybroeck; Richard Wilson; Elaine W Kay; Daniel B Longley; Patrick G Johnston Journal: Clin Cancer Res Date: 2010-06-22 Impact factor: 12.531
Authors: Wendy L Allen; Leanne Stevenson; Vicky M Coyle; Puthen V Jithesh; Irina Proutski; Gail Carson; Michael A Gordon; Heinz-Josef D Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston Journal: Mol Cancer Ther Date: 2011-10-25 Impact factor: 6.261
Authors: S J Kimber; S F Sneddon; D J Bloor; A M El-Bareg; J A Hawkhead; A D Metcalfe; F D Houghton; H J Leese; A Rutherford; B A Lieberman; D R Brison Journal: Reproduction Date: 2008-05 Impact factor: 3.906
Authors: Ji Luo; Michael J Emanuele; Danan Li; Chad J Creighton; Michael R Schlabach; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge Journal: Cell Date: 2009-05-29 Impact factor: 41.582
Authors: C Sakamoto; H Kohara; H Inoue; M Narusawa; Y Ogawa; L Hirose-Yotsuya; S Miyamoto; Y Matsumura; K Yamada; A Takahashi; K Tani Journal: Cancer Gene Ther Date: 2017-01-13 Impact factor: 5.987
Authors: Andrea Martins-da-Silva; Mirella Baroni; Karina Bezerra Salomão; Pablo Ferreira das Chagas; Ricardo Bonfim-Silva; Lenisa Geron; Gustavo Alencastro Veiga Cruzeiro; Wilson Araújo da Silva; Carolina Alves Pereira Corrêa; Carlos Gilberto Carlotti; Rosane Gomes de Paula Queiroz; Suely Kazue Nagahashi Marie; Silvia Regina Brandalise; José Andrés Yunes; Carlos Alberto Scrideli; Elvis Terci Valera; Luiz Gonzaga Tone Journal: Cell Mol Neurobiol Date: 2022-04-02 Impact factor: 5.046